Optimal sequencing of the first-and second-line target therapies in metastatic renal cell carcinoma: Based on nationally representative data analysis from the Korean National Health Insurance System

The authors intend to compare the effects of each targeted therapy (TT) in the treatment of patients with metastatic renal cell carcinoma (mRCC) using big data based on the Korean National Health Insurance System (NHIS) and determine the optimal treatment sequence.